Advertisement
Singapore markets closed

  • Straits Times Index

    3,314.14
    +8.12 (+0.25%)
     

  • S&P 500

    5,462.99
    -1.63 (-0.03%)
     

  • Dow

    39,230.65
    +80.32 (+0.21%)
     

  • Nasdaq

    17,667.45
    -21.91 (-0.12%)
     

  • Bitcoin USD

    61,230.38
    -3,020.71 (-4.70%)
     

  • CMC Crypto 200

    1,259.46
    -50.26 (-3.84%)
     

  • FTSE 100

    8,273.35
    +35.63 (+0.43%)
     

  • Gold

    2,339.00
    +7.80 (+0.33%)
     

  • Crude Oil

    80.26
    -0.47 (-0.58%)
     

  • 10-Yr Bond

    4.2590
    +0.0020 (+0.05%)
     

  • Nikkei

    38,804.65
    +208.18 (+0.54%)
     

  • Hang Seng

    18,027.71
    -0.81 (-0.00%)
     

  • FTSE Bursa Malaysia

    1,589.66
    -0.71 (-0.04%)
     

  • Jakarta Composite Index

    6,889.17
    +9.19 (+0.13%)
     

  • PSE Index

    6,272.46
    +113.98 (+1.85%)
     

Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Zacks Equity Research
·2-min read

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.

While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.

Why Investors Should Pay Attention to This Value Stock

Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.

ADVERTISEMENT

United Therapeutics (UTHR)

Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use.

UTHR sits at a Zacks Rank #3 (Hold), holds a Value Style Score of B, and has a VGM Score of A. Compared to the Medical - Drugs industry's P/E of 13.9X, shares of United Therapeutics are trading at a forward P/E of 11.2X. UTHR also has a PEG Ratio of 4.1, a Price/Cash Flow ratio of 12.5X, and a Price/Sales ratio of 4.9X.

A company's earnings performance is important for value investors as well. For fiscal 2024, seven analysts revised their earnings estimate higher in the last 60 days for UTHR, while the Zacks Consensus Estimate has increased $0.85 to $24.62 per share. UTHR also holds an average earnings surprise of 12.4%.

UTHR should be on investors' short lists because of its impressive earnings and valuation fundamentals, a good Zacks Rank, and strong Value and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

United Therapeutics Corporation (UTHR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research